Kroetz, D.L.

irinotecan patient diarrhea ugt 1a sn -38 cancer pharmacokinetic haplotype genotype abcc 2 -38 variant polymorphism sn -38g allele abcc 2*2 haplotype number ugt 1a allele toxicity transporter 2*2 ratio presence frequency transport activity metabolite cancer res effect ugt 1a genotype study signi oncol clearance expression table biliary analysis protein abcc 2 gene irinotecan-induced diarrhea grade capacity neutropenia signi ficantly ta-repeat grade 3 glucuronidation treatment hepatobiliary secretion exposure syndrome population extent variability irinotecan-induced january association pharmacology blood region volume relationship promoter region article plasma concentration occurrence irinotecan therapy plasma pharmacogenetic fidence interval signi ficant interval index value metabolism caucasian promoter therapeutic molar